CDKN2A and rheumatoid arthritis: Intra-articular gene transfer of tumor-suppressive genes, such as the senescence-promoting p16INK4a and p21CDKN1A cell-cycle inhibitors, has been used in preclinical RA joint models with the aim of delaying/preventing these invasive and hyperproliferative stromal phenotypes [61,62,63,64].